Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tasly Pharmaceutical Group CoSHSE:600535 -3.45%78 Return-on-Tangible-Equity is 14.13% as of Mar. 2026, which is 24% above its 10-year median of 11.35. GuruFocus rates SHSE:600535 with a GF Score™ of 78/100 and a GF Value™ of ¥15.07 (Fairly Valued). The stock has 1 warning sign investors should review. Among 901 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 60.27% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Tasly Pharmaceutical Group Co's annualized net income for the quarter that ended in Mar. 2026 was ¥1,481 Mil. Tasly Pharmaceutical Group Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥10,483 Mil. Therefore, Tasly Pharmaceutical Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.13%.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600535'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2.4 Med: 11.35 Max: 21.94
Current: 11.29
During the past 13 years, Tasly Pharmaceutical Group Co's highest Return-on-Tangible-Equity was 21.94%. The lowest was -2.40%. And the median was 11.35%.
SHSE:600535's Return-on-Tangible-Equity is ranked better than 60.27% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs SHSE:600535: 11.29
Tasly Pharmaceutical Group Co (SHSE:600535) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Tasly Pharmaceutical Group Co Return-on-Tangible-Equity Related Terms
Tasly Pharmaceutical Group Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co Return-on-Tangible-Equity Chart
SHSE:600535 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.13% mean?
Tasly Pharmaceutical Group Co (SHSE:600535) has a Return-on-Tangible-Equity of 14.13% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 24% above median its historical median of 11.35. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #358 out of 901 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity too high?
Tasly Pharmaceutical Group Co's current Return-on-Tangible-Equity of 14.13% is 24% above median its 10-year median of 11.35. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Tasly Pharmaceutical Group Co's value of 14.13% is 78.9% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #358 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #358 out of 901 companies for Return-on-Tangible-Equity. This puts Tasly Pharmaceutical Group Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Tasly Pharmaceutical Group Co's value of 14.13% is 78.9% above this benchmark. While the company's 10-year median is 11.35 vs. the industry median of 7.90, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Return-on-Tangible-Equity of 14.13% is 78.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Return-on-Tangible-Equity is 14.13%, which is 24% above median its own 10-year median of 11.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.07, compared to a current price of ¥15.38 — trading 2.1% above its estimated fair value. The current Return-on-Tangible-Equity is 14.13%, which is 24% above median its 10-year median of 11.35 and 78.9% above the Drug Manufacturers industry median of 7.90. Tasly Pharmaceutical Group Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Return-on-Tangible-Equity is 14.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥15.38 is trading 2.1% above its estimated GF Value™ of ¥15.07.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
Return-on-Tangible-Equity: 14.13% (24% above median its 10-year median of 11.35)
GF Value™: ¥15.07 vs. price of ¥15.38 (2.1% above fair value)
Industry Position: 78.9% above the Drug Manufacturers median (#358 of 901)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
78GF Score
Get the complete analysis for SHSE:600535
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
